Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 GlobeNewswire - Wed Dec 10, 7:30AM CST

THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as...

LXRX : 1.3200 (+0.76%)
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum GlobeNewswire - Fri Dec 5, 7:30AM CST

THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin...

LXRX : 1.3200 (+0.76%)
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences GlobeNewswire - Tue Nov 25, 7:30AM CST

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler...

LXRX : 1.3200 (+0.76%)
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference GlobeNewswire - Tue Nov 11, 7:30AM CST

THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025...

LXRX : 1.3200 (+0.76%)
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 GlobeNewswire - Sat Nov 8, 1:30PM CST

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific...

LXRX : 1.3200 (+0.76%)
Lexicon: Q3 Earnings Snapshot AP - Thu Nov 6, 6:47AM CST

Lexicon: Q3 Earnings Snapshot

LXRX : 1.3200 (+0.76%)
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates GlobeNewswire - Thu Nov 6, 6:30AM CST

FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation...

LXRX : 1.3200 (+0.76%)
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans GlobeNewswire - Tue Nov 4, 7:30AM CST

THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.   (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming...

LXRX : 1.3200 (+0.76%)
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 GlobeNewswire - Thu Oct 30, 7:30AM CDT

THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November...

LXRX : 1.3200 (+0.76%)
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit GlobeNewswire - Tue Oct 14, 7:00AM CDT

– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas,...

LXRX : 1.3200 (+0.76%)

Barchart Exclusives

Jamie Dimon Has Long Been Sounding the Economic Alarm. After the Fed’s Latest Rate Cut, Can You Still Bank on JPMorgan Stock? Barchart - Wed Dec 10, 8:10PM CST
A nearly 5% plunge in JPM shares on Tuesday is reason for caution with the leader of U.S. bank stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot